Compare Boston Scientific Corporation (BSX) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Quantum Computing Inc — how do they compare? Boston Scientific Corporation trades at $51.37 (market cap $74.19B), while Quantum Computing Inc trades at $8.95 (market cap $2.03B). The key difference: Boston Scientific Corporation is far larger — about 36.5× Quantum Computing Inc's market cap. Which is the better fit depends on your goals.
| BSX | QUBT | |
|---|---|---|
Market Cap | $74.19B | $2.03B |
Sector | Health | Technology |
52-Week High | $108.14 | $24.62 |
52-Week Low | $42.63 | $6.31 |
Enterprise Value | $86.27B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Quantum Computing Inc. (QUBT) trades at $9.07, up 1.57% with bearish technical signals despite recent revenue growth. The company reported Q2 2026 revenue of $5.6 million, a significant increase from prior periods, though profitability remains challenged with negative margins. Analyst consensus is bullish with a $18.50 price target, while institutional interest grows with recent purchases by Amundi and Bank of New York Mellon.
QUBT presents high-risk, high-reward potential with strong revenue growth from photonics sales but faces execution risks and negative profitability. The stock's 75% buy rating from analysts suggests upside potential, though investors must weigh the speculative nature against substantial cash reserves and expanding manufacturing capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
